Driving innovation in Galectin-3 targeted therapeutics to
address significant unmet clinical needs in cancer and fibrosis

About Galytx

Galytx is a biotech company that develops galectin-3 targeted novel therapeutics.

Galectin-3 is a molecular target of exceptional clinical relevance in cancer, fibrosis and inflammation. Over expression of galectin-3 is an important driver of morbidity and morality associated with these diseases. Galytx is developing a unique portfolio of first in class, non-carbohydrate, wholly synthetic small molecule assets that target galectin-3 to address the  significant unmet clinical need in these disease areas.

Our pipeline includes both clinical and pre-clinical assets. Our lead clinical asset is a repurposed drug that has a strong and well-established safety record in chronic oral use, that enables a fast-track clinical development pathway. Our pre-clinical assets will be developed to produce high potency injectable therapeutics for acute use. Our lead disease indications are triple negative breast cancer and chronic heart failure, with our future vision to extend to address the full spectrum of galectin-3-mediated pathologies

Galytx Ltd is a limited company incorporated in England with registered number 15233016.  Registered address: Foundation Building, Brownlow Hill, Liverpool, England, L69 7ZX